BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/13/2021 12:57:54 PM | Browse: 485 | Download: 977
 |
Received |
|
2021-02-21 14:56 |
 |
Peer-Review Started |
|
2021-02-21 14:59 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2021-06-16 02:16 |
 |
Revised |
|
2021-06-19 11:47 |
 |
Second Decision |
|
2021-08-24 03:23 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2021-08-24 08:13 |
 |
Articles in Press |
|
2021-08-24 08:13 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2021-09-30 08:31 |
 |
Publish the Manuscript Online |
|
2021-10-13 12:57 |
ISSN |
1948-5204 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Oncology |
Manuscript Type |
Review |
Article Title |
Molecular testing for colorectal cancer: Clinical applications
|
Manuscript Source |
Invited Manuscript |
All Author List |
Evgeny Imyanitov and Ekaterina Kuligina |
ORCID |
|
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Ministry of Science and Higher Education of the Russian Federation |
075-15-2020-789 |
|
Corresponding Author |
Evgeny Imyanitov, DSc, Professor, Department of Tumor Biology, N.N. Petrov Institute of Oncology, Pesochny, St.-Petersburg 197758, Russia. evgeny@imyanitov.spb.ru |
Key Words |
Colorectal cancer; Anti-epidermal growth factor receptor therapy; KRAS; NRAS; BRAF; HER2; Microsatellite instability; MUTYH; Hereditary cancer |
Core Tip |
Molecular genetic analysis is an integral component of colorectal cancer (CRC) management. Comprehensive KRAS and NRAS testing is mandatory for selection of patients for anti-epidermal growth factor receptor (EGFR) therapy. BRAF V600E mutated cancers are responsive to combination of BRAF and EGFR inhibitors. CRCs with HER2 amplification and overexpression can be controlled by the down-regulation of this receptor. Immune therapy is highly effective in CRCs with exceptionally high tumor mutation burden, e.g., in cancers with microsatellite instability, MUTYH gene inactivation or mutations in the POLE gene. CRC patients with early disease onset, specific tumor features or family history of the disease require germ-line DNA testing. |
Publish Date |
2021-10-13 12:57 |
Citation |
Imyanitov E, Kuligina E. Molecular testing for colorectal cancer: Clinical applications. World J Gastrointest Oncol 2021; 13(10): 1288-1301 |
URL |
https://www.wjgnet.com/1948-5204/full/v13/i10/1288.htm |
DOI |
https://dx.doi.org/10.4251/wjgo.v13.i10.1288 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345